Pod Insights The Dentalpreneur Podcast Dr. Mark Costes 2127: Deal Structures, Equity, & Negotiation Tactics Pt. 2 About this episode On today's episode, we continue with Brandon Moncrief of McLerran & Associates, a leading expert in dental transitions and DSO affiliations, to dive deep into the intricacies of holdco equity, joint venture structures, and maximizing practice valuations. Brannon explains the nuances of DSO deal structures, including the benefits and risks of holdco equity versus joint venture (JV) models, and how these choices align with a dentist's career stage and goals. He shares actionable insights on what makes a DSO attractive to private equity firms and the critical factors that can influence valuation multiples at recap. Listeners will also learn about common mistakes dentists make when selling their practice, how to avoid being undervalued, and why proper representation and creating competitive market leverage are essential. Brannon reveals how his firm’s sell-side advisory process can increase valuations by 30-50% through strategic negotiation and a blind bidding process. If you’re considering a DSO affiliation or just want to understand the evolving landscape of dental practice consolidation, this episode is packed with invaluable advice to help you navigate these high-stakes decisions with confidence. EPISODE RESOURCES https://dentaltransitions.com https://www.truedentalsuccess.com Dental Success Network Subscribe to The Dentalpreneur Podcast
Transcript 0:08 Speaker 00 This episode is being brought to you by the dental event of the year, the 12th Annual Dental Success Summit, set for June 12th through 14th, 2025, at the beautiful Omni PGA Resort and Spa in Frisco, Texas. Join us as some of our profession's top educators deliver world-class tactical and strategic knowledge to help elevate your career, your business, and your personal life. This year, we've added multiple educational tracks in order to provide value for your entire team. We're also thrilled to announce our two phenomenal keynote speakers. The first is Ryan Holiday, multiple New York Times bestselling author, and one of the world's most respected
0:48 Speaker 00 purveyors of ancient Stoic philosophy. And the second is Erica Duan, a global authority on teamwork and innovation. Right now, you can grab your tickets at an incredible 55% off, but only through January 5th. Don't miss this chance to secure your seat at the lowest price. For more information and to register, just go to truedentalsuccess.com. That's truedentalsuccess.com. Can't wait to see you in Frisco.
1:28 Speaker 00 This episode is being sponsored by our good friends over at Gusto. Running a dental practice is hard work, but payroll and HR don't have to be. Gusto takes the pain out of payroll, benefits, onboarding, and more. With Gusto, you can automatically file and pay payroll taxes, deposit paychecks, and offer benefits like health insurance and 401k. Plus, listeners get three months free when they run their first payroll. Try it out today at gusto.com/dentalpreneur. That's gusto.com/dentalpreneur.
2:06 Speaker 01 The Dentalpreneur Podcast. Okay, doctor, it's time to put down that handpiece. You're listening to the show dedicated to helping dentists get their lives back. It's time to decrease your stress, increase your profitability, and regain your passion. Now introducing your host, Dr. Mark Kostas.
2:29 Speaker 00 Hello everyone, welcome to another episode of the Downpour Podcast. I'm your host, Dr. Mark Costas. What's up my friends? This is part two of a two-parter featuring my good friend, Brandon Moncrief from McLaren and Associates. He is an expert in all things DSO transition. He has been in the game for over a decade and we talk about a lot of things, including how recaps are calculated, what the whole kind of process is for sell-side advisory and actually negotiating with DSOs. The fact that in most cases, the DSO will try to beat you up on EBITDA and inflate the multiple to make it seem as though you're getting a good deal and the importance,
3:11 Speaker 00 obviously, of having an advisor in those types of situations. He goes over the top mistakes that dentists make when pursuing a DSO affiliation and he debunks a ton of myths about DSO affiliations. All right, guys, I hope you enjoy this part two episode. One of the smartest guys when it comes to DSO transitions, Brandon is the real deal. Let me know what you think and we'll talk to you soon. Bye-bye. Tell me if I understand this correctly about holdco equity versus joint venture deals. It's less likely that you'll get a significant amount of holdco equity as a DSO grows. True or false?
3:48 Speaker 02 I'd say that that's false.
3:49 Speaker 00 Okay.
3:50 Speaker 02 It really depends on the DSO's deal structure. I mean, some DSOs are a pure holdco where they're going to be giving you 60, 70, 80% cash at close and the remaining value of your business is going to be rolled in a stock in the holding company of that DSO. Whereas others are pure joint venture, you know, 60, 70% cash at close, 30 to 40% JV equity at the practice level. And then others are a hybrid, a combination of those two models where it might be 60% cash at close, 20% JV equity, 20% holdco. But I have not found that as the DSO grows in size, the amount of holdco changes
4:32 Speaker 02 as far as how much you can invest in the parent company, especially what we've experienced over the past couple of years.
4:42 Speaker 02 Capital markets are relatively tight.
4:45 Speaker 02 DSOs are trying to make their cash go further. And the way to make your cash go further is to have a larger component associated with equity so that you can reserve cash and continue to buy more practices and grow at a faster clip.
5:01 Speaker 00 Yeah, that makes sense. I just, I mean, when I picture like a pie, you know, private equity has to have their piece. The founding members have to have their piece of equity. So there's a finite amount of equity that you can distribute to future quote unquote, partners or purchasers, people that you've purchased. So it just seems to me at some point with certain scale, you're just going to run out of hold co-equity.
5:27 Speaker 02 Well, I think that's the reason why you have to hit a recapitalization event, right? To create that liquidity event so that the private equity firm can then up their equity position and kind of start the process over again.
5:38 Speaker 00 Makes sense. Yeah. Yeah. So
5:42 Speaker 00 what is your, what is your preferred method? I mean, one of the cool things, obviously, about a JV model is that you still get some form of cash flow from some percentage of EBITDA that flows back to you. They, they own the majority of it, but you own a minority of it. And so you, you have certain cash flow assurances and then you have, if you, if you remain profitable. And that's incentivized, that incentivizes you for growth as well. So how, how do you prefer, what, what is your preferred structure if you could choose?
6:14 Speaker 02 So I try to take a relatively agnostic approach to, you know, how we market the, our clients' businesses. So we always tell our clients, hey, keep an open mind. Let us take the practice to the broad marketplace, bring you all different types of buyers from a size perspective, from a deal structure perspective, and allow you to meet the players and get educated as to who's out there. And that may change your opinion as to what type of deal structure or what type of DSO you want to affiliate with. If you're younger, I do like the JV and hybrid deal structure because that is true retained equity at the practice level that you will receive ongoing pro-rata EBITDA
6:55 Speaker 02 distributions associated with that equity. So you don't take as big of a hit in your personal income.
7:01 Speaker 00 Right.
7:01 Speaker 02 In a hybrid or JV deal structure comparative to a holding company structure. Also, in some ways, I would say that the JV equity has less risk because it has real value associated with those EBITDA distributions. Whereas in the holdco model, that holding company equity, you are betting solely on a recap. There's no distributions associated with that equity along the way. So for most of our younger doctors, they tend to gravitate and I tend to push them towards a JV or hybrid structure. You know, a lot of our doctors that are close to the tail end of their career like the holding company model because there is a higher probability you're going to be able to liquidate a higher percentage of your equity at recap in a holding company model comparative to a JV model. In a JV
7:46 Speaker 02 or hybrid model, the DNA of that DSO is designed so that there's always a doctor partner at the practice level. So there's always going to be some element of joint venture equity that has to be owned by a doctor. So if and when you go to divest your remaining equity in your business under a JV structure, you're likely going to have to sell some part of that equity to another individual doctor and that might be more difficult than liquidating holdco in a recap.
8:17 Speaker 00 Got it. Okay. What are some factors that affect that multiple at recap? So, you know, you know, people are like, oh, we nailed it. We went from, you know, a blended EBIT of nine to a 14. So what, what is, I mean, other than, you know, economic cycles, what are predictably some things that will increase that multiple on invested capital?
8:43 Speaker 02 So we talked about it a little bit earlier. I mean, it comes down to infrastructure, same-store sales growth and also just how much you've grown.
8:55 Speaker 00 How much? Yeah, just from all directions. How much equity?
8:58 Speaker 02 From all directions.
9:00 Speaker 00 Right, okay.
9:00 Speaker 02 Right. How much EBITDA have you added through acquisitions? How much EBITDA have you added through same-store sales growth? Are the underlying assets within the portfolio healthy and growing? Do you have real infrastructure? Do you have a real management team? And is your deal structure thoughtful and sustainable long-term? Those are all the things that are going to impact the exit multiple. Now, in a joint venture or hybrid structure where you're liquidating some joint venture equity at a recap, it's also the practice level EBITDA that's going to impact your proceeds. Because in that scenario, when you're liquidating joint venture equity, all of the things I just named, that's what impacts the multiple of the parent company, right? But if you're liquidating JV equity,
9:45 Speaker 02 the proceeds you're going to receive at liquidation are predicated on the parent company multiple times the practice level EBITDA. And that's why so many DSOs like a JV structure because you have pure alignment with your partners at the practice level. Because as EBITDA grows at the practice level, not only does the DSO's equity in your business grow in value, but your own equity in your business grows in value.
10:09 Speaker 00 Yeah, that's really good. Okay, so you're probably sick to death of this question, but I have to ask it just in case people haven't listened to you and I talked before. If you could pick two or three of the main mistakes that people make when they're selecting a DSO or when they're selling in general, because there's a lot of shady outfits out there and there's a lot of very, very aggressive sale, quote-unquote, salespeople, these business development managers that go out and will promise you the world and they make their, you know, four to 10% commission on the deal and they're gone forever. You'll never speak to them again. So what are some of the main kind of mistakes that people make when they're vetting their own, their own personal deals?
10:53 Speaker 02 The first and foremost, you need to define your why, you need to find your goals, and you need to get educated. You need to get educated by somebody that takes an objective approach to that conversation. That's what we try to do with each and every one of our clients. So you've got to understand, what are you trying to accomplish? What is your EBITDA? What is your business worth in the DSO environment? And how does selling to a DSO under different deal structures and at a certain valuation compare to keeping your head down and hanging on to your business? I think that's where the conversation has to start. And you need to work with somebody that can give you objective guidance
11:35 Speaker 02 that is not going to push you one direction or the other. Secondly, you need to make sure that if you're going to go down this path, you create as much optionality and leverage as possible through doing two things. You've got to have a great team of advisors. You really need a sell-side advisor because that's what we do. We create optionality, we create leverage, we create a multiple offer situation, which is going to ultimately allow you to choose the right partner for your individual situation and practice, and then create the leverage necessary to maximize your deal terms and valuation. So all too often, we see doctors that they respond to an unsolicited offer,
12:19 Speaker 02 or they end up by default selling to a DSO that their buddy sold to because their colleague introduced them to this DSO, talked them up, and said, "Hey, I've had a good experience. You need to talk to them. You should sell to them." What they fail to disclose a lot of times is that they're getting paid by the DSO to make that referral, and they may not be altruistic in the guidance that they're giving you. And even if you want to sell to that particular DSO, you still need to hire a sell-side advisor to hold that DSO's feet to the fire, to create that competitive environment, create that leverage to get the best terms you can get from that particular buyer. And a lot of our clients, probably 50% of them,
13:01 Speaker 02 are already in serious discussions with the DSO or have an offer on the table. And they may like that DSO, but they don't understand that that offer could be substantially better if...
13:16 Speaker 02 They kind of reset the playing field by hiring a great team of advisors and creating competitive environment for their practice. And I could tell story after story of doctors that thought they had a good offer in hand and they wisely hired us to represent them. We created that hyper competitive environment. We controlled the narrative regarding EBITDA and they ultimately sold to the same DSO they were already talking to previous to engaging us at 20, 30% higher valuation, simply by holding that DSO's feet to the fire and entertaining offers from other suitors. And that brings me to the third point, and that is controlling the narrative regarding EBITDA. The number one way that DSOs are opportunistic is they
14:00 Speaker 02 convince doctors that your EBITDA is substantially lower than it is, but dangle the carrot of a sexy EBITDA multiple. So, for example, we get hired by clients all the time that say, hey, I've got an offer in hand from a DSO. My EBITDA is 500,000 and they've offered me a 7X. And that sounds like a reasonable deal. So I've got a $3.5 million offer from a DSO that a couple of my buddies sold to and I like them. I want to sell to them. Does this make sense to you? And I say, well, why don't you hire us to do evaluation? Let's do our own independent EBITDA analysis, gut check that EBITDA, make sure that it's fair. And then we'll also gut check the multiple to make sure that the multiple is at market.
14:45 Speaker 02 And we'll do our own EBITDA analysis and discover that EBITDA is actually 700,000 and that 7X multiple is actually a 5X multiple. And at that point, it's like timeout. They are trying to take advantage of you because you don't have proper representation. We need to take the practice to the open market, including reapproaching them with our own EBITDA analysis and negotiate a much better valuation, even if we can't move the needle on the multiple, which we likely can't move the needle on the multiple half a turn to a turn. If we're able to get full credit for your EBITDA.
15:27 Speaker 02 Your EBITDA was 500,000 at a 7X, that's a $3.5 million unsolicited offer. Your EBITDA is actually $700,000 at a 7X. That's a $4.9 million offer, a $1.4 million increase, and we haven't even touched the multiple yet. If we're able to get five, six, seven other offers and then move the multiple by half a turn, now all of a sudden, that $4.9 million offer is 5.25 million comparative to the unsolicited offer of 3.5 million. That's a 50% increase in valuation, simply by controlling the narrative regarding EBITDA, creating a competitive environment, and getting you an extra half turn on the multiple.
16:14 Speaker 00 This episode is being brought to you by my good friends at McLaren and Associates. The team at McLaren specializes in providing sell-side advisory to larger practice owners seeking a DSO affiliation or private equity partner. Their proven DSO affiliation process is designed to educate you regarding your EBITDA, ensure you find the right partner for your practice, and maximize your outcome from the sale. McLaren has worked with many of our listeners to achieve amazing results. To learn more about the value of your practice and options available in today's marketplace, just reach out to Brandon Moncrief at 512-660-8505, or go to dentaltransitions.com.
16:57 Speaker 00 That's 512-660-8505, or go to dentaltransitions.com. Monetizing your business is one of the most impactful decisions on your life, so make sure you're working with the best. McLaren and Associates.
17:18 Speaker 00 Have you found that there's almost always room for negotiations? Because they'll make you believe that here's our boilerplate. We don't do anything different for any other doctors. Here's our calculations. Take it or leave it. I think that probably depends on the market cycle and the economic environment, maybe, or the strength of the practice. But have you found that there's always wiggle room?
17:42 Speaker 02 The DSOs are going to try to convince you not to hire me, right? Because they know what happens when you hire me, what I just explained. We have never accepted an unsolicited offer at the terms that our client came to us at.
18:00 Speaker 00 No, never.
18:01 Speaker 02 So there is always, we have never accepted
18:04 Speaker 00 That's crazy.
18:04 Speaker 02 the offer as it sat. So there's always been room to negotiate. I mean, if they know that they're talking to you alone with no other competition and no advisor, what motivates them to be altruistic and give you the last dollar they can pay for the practice? The first offer is never the best offer. In fact,
18:28 Speaker 02 it has been extremely rare that even with us running our process, that we have ever accepted the initial offer that a DSO made to one of our clients. We always negotiate initial offers. And those initial offers are typically 10 to 20% higher than the unsolicited offer, right? So the unsolicited offer is way down here. We come in, do our job, create that competitive environment. The initial offers that our clients receive with us involved in the process are 10 to 20% better than the unsolicited offer. And then we negotiate from there. And that's why oftentimes the end result is an LOI valuation inked at
19:12 Speaker 02 a 30%, 40% premium compared to that initial unsolicited offer.
19:17 Speaker 00 That makes sense. What are some of the ways that they can kind of manipulate your EBITDA? I mean, it seems like it's arithmetic, right? You have, you have standard add backs and you have like, here's how much we generated. So how can they manipulate that?
19:32 Speaker 02 Should be standardized, but it's not. If you give your numbers to 10 different DSOs, you're going to get 10 different EBITDA figures in return. A lot of the ways that they manipulate EBITDA is they don't give you credit for, you know, one-time, non-recurring costs. They don't give you full credit for, you know, personal and discretionary expenses. They layer in infrastructural costs into your practice. Well, you know, we're going to provide these services, or we have to provide these benefits, and therefore, you know, those costs are going to sit on your P and L and erode your EBITDA. There's all different types of tricks. I mean, primarily what they try to do is just take your EBITDA at face value
20:17 Speaker 02 without making all the necessary adjustments to account for all the things that I just mentioned.
20:22 Speaker 00 Yeah.
20:23 Speaker 02 And if you're not wise to that, you're going to leave a ton of money on the table because every dollar of EBITDA is worth $7 to $10 in value. So the multiple is not the most important thing impacting the valuation. The EBITDA is the most important thing impacting the valuation. If you can negotiate both of those elements of the transaction, you're going to end up with a much better result.
20:46 Speaker 00 Yeah, that's so interesting. And coming back to your kind of, your explanation about blended EBITDA. Obviously, you know, if you are a shrewd negotiator, you may be one of the practices that they paid a premium for, and then there's going to be a handful of practices that they underpay for. So that blended EBITDA is going to be in the accepted range for them. And as long as, as long as that accepted blended EBITDA is okay, so they're willing to pay a premium, and then they know that there's going to be some unsophisticated sellers as well, correct?
21:21 Speaker 02 Absolutely. So a lot of people ask me, well, Brendan, how are you able to do this? Why, why will DSOs pay a premium for my practice?
21:32 Speaker 02 comparative to, you know, me doing this on my own. And the reality is this, it's a cost average game. Like you said, let's say they're going to go buy 10 practices in Phoenix, Arizona. Because they've created such efficient marketing channels to get proprietary deals. Doctors that come to them that are unrepresented. They know they can manipulate EBITDA, evaluate valuation on those deals. And those are the majority of the practices they're going to buy. So let's say they buy eight of those 10 practices unrepresented. They had no competition and they bought those practices for five and a half times EBITDA. Their goal was to buy those 10 practices at a cost average of seven times EBITDA.
22:13 Speaker 02 Well, if they bought eight at five and a half times EBITDA, that means that the two clients that I represent that sell with that same DSO, they can afford to pay eight, eight and a half times EBITDA for those practices because they just blend them all together. It's a cost average game and that's why we're able to create those central arbitrage for our clients because DSOs are buying so many practices directly from doctors at Undermarket.
22:39 Speaker 00 Great, great. Okay. So explain to me your business model then. Do you, do you have listings? Do you have listings that you are representing? Kind of like a traditional broker? Or do you skew more towards sell-side advisory? Or is it kind of a blended mix of the two services?
22:58 Speaker 02 So we call ourselves sell-side advisors. I think that's a more professional term that describes what we do comparative to broker that I think kind of have as a negative connotation. So the way we function with all of our clients, it starts with a confidential casual discovery call, 30 minutes to get to know each other, understand your why, talk a bit about the aspects of your practice, if it makes sense to do a deep dive, to do evaluation, to unpack, what is your EBITDA? What would the practice trade for in the DSO environment? What are all the different deal structures out there? And then what does the no sales scenario look like comparatively speaking? Get you educated. And then from there, let's say you say, hey, this is a fit. I want to work with you guys.
23:43 Speaker 02 Go represent me and create that competitive landscape. Bring me multiple offers from DSOs. We're going to sign a listing agreement, authorizing us to take the practice to market. And then our job is essentially to create a bidding war, right? To help you find the right partner, maximize the deal terms and maximize the valuation. And shepherd you through that process from start to finish. And then we're paid a success fee, a commission if and when the sale comes to fruition. And when we take a practice to market, we utilize what we call a blind bid process. So the valuation conversation is a private conversation between us and the client to really just set baseline expectations as to what we think we can achieve in the marketplace.
24:27 Speaker 02 But when we take the practice to market, we utilize a blind bid process so that we don't leave a single dollar of value on the table. At any given time, we've got 50 or so practices on market. Now, the legacy business that I purchased 13 years ago is more of like the doctor to doctor traditional practice sales business. That business still exists. So we sell about 50 practices a year to individual clinicians. And then we sell another 40 to 50 practices a year to DSOs and private equity. And that's the team that I lead on a daily basis. So at any given time, we've got, say, 25, you know, private buyer deals on market,
25:08 Speaker 02 25 DSO private equity deals on market, all across the country and every different specialty. So right now, we've got a couple of Endo practices, a couple of Perio practices. We've got five OMS offices, a couple of PTO, a couple of ortho, and the rest are general. So we work coast to coast. We have an office in Austin, Atlanta, and San Diego. And we've now closed well over 200 DSO transactions, representing about 1.5 billion in transaction volume. This is what we eat, sleep, and breathe, you know, day in, day out.
25:43 Speaker 00 Dude, so cool. So you developed the kind of DSO branch of McLaren Associates yourself. So you created this other leg of the business from scratch, basically.
25:57 Speaker 02 Yeah, six years ago, we made the decision, you know, being based in Texas, we were kind of on the forefront of a lot of the consolidation. A lot of consolidation started in Arizona, Texas, and Florida, and it's now obviously spread to the rest of the country. But we were watching some of our premier, what we thought were going to be private buyer clients decide to go the DSO route. And a lot of them were not educated about how private equity views, practice, valuation, about the different levers involved in the deal structure. They either sold prematurely to the wrong DSO or left a lot of money on the table. And it was like, all right, we've got to get involved in this side of the space. That's when we built out a process, a DSO
26:38 Speaker 02 affiliation and private equity partnership process. We built out a valuation team consisting of a CPA and multiple financial analysts. And then we started to recruit investment bankers and people that were working on the buy side for DSOs. So, you know, we've got a former investment banker on our team. We've got a couple of guys that were working on the buy side for private equity backed DSOs. We invited them to step on the sell side of the table. You know, who better to have representing you than somebody that knows all the tricks of the trade and used to sit on the buy side? Yeah. So we've got a team of 13 people, likely about to be 15 people nationwide. And it's
27:17 Speaker 02 been a really fun ride. We built an awesome reputation in the space and really enjoy what we do. And, you know, we create meaningful value for our clients, whether that's educating them and convincing them that a DSO affiliation isn't the right path for them, or educating them and helping them monetize their business at a much better outcome than they would achieve on their own.
27:42 Speaker 00 Good stuff, buddy. Good stuff. What's the best way for people to kind of start that discovery process with your team?
27:49 Speaker 02 Yeah, you can text me, you can call me on my cell. My number is 512-660-8505. You can also email me, Brandon, B-R-A-N-N-O-N, at dentaltransitions.com. And check out dentaltransitions.com. There's a DSO Resources landing page that's got a lot of articles and podcasts and webinars just like this one, because we're all about getting educated. You gotta get educated first before you make one of the most impactful decisions of your career in your life.
28:25 Speaker 00 Yeah, bottom line, don't be scared of DSOs. Just go in with representation if you're considering selling to a DSO.
28:31 Speaker 02 Absolutely.
28:32 Speaker 00 Love it. All right. All right, guys. As always, Brandon, just one of the best minds in this space. So I can't thank you enough for taking the time to talk to our audience today. You always bring fresh insights, no matter how many times we talk. Congratulations on your, on your success. You've been busier than anybody in the industry. And let's look to see what happens with this new administration's gonna do for this whole transition world. It's gonna be interesting.
28:59 Speaker 02 I'm definitely bullish on it. Thanks for having me, Mark. Always a pleasure.
29:02 Speaker 00 All right. Ladies and gentlemen, Brandon Moncrief.
29:07 Speaker 00 Is your practice recession-proof? We've got the solution. Just download the free essential checklist for recession-proofing your dental practice and watch our expert-led webinar featuring Dr. Addison Colleen, Dr. Ben Kakis, and Ryan Gross. During the webinar, you'll learn how to protect your cash flow, cut unnecessary expenses, and optimize your operations for long-term success. Plus, get a seven-day free trial to the Dental Success Network, where you'll access tools, resources, and exclusive savings to help your practice thrive. To take advantage of this offer, just go to dentalsuccessnetwork.com/recproof. That's dentalsuccessnetwork.com/recproof to get started today.
29:57 Speaker 00 Thank you for taking the time out of your busy schedule to listen to today's podcast. As you know, the fundamentals of a good business are universal. A solid flow of new customers, systemization, human resources, and cash flow. That's exactly what I cover in my first book, Pillars of Dental Success. If you'd like a free downloadable copy and other valuable practice building resources, just go to dentalsuccessnetwork.com/pillars. That's dentalsuccessnetwork.com/pillars. We'll see you at the next episode.
30:39 Speaker 00 And that wraps it up for another episode of the Dental Preneur Podcast. Look forward to reconnecting on the next episode.
30:49 Speaker 01 Thank you so much for joining us today on the Dental Preneur Podcast. Check out truedentalsuccess.com for full recaps of every show, a schedule of our live events, free video tutorials, and a whole host of practice building resources.
Previous 2126: Deal Structures, Equity, & Negotiation Tactics Pt. 1 Next 2128: Scaling Global Impact Pt. 1 Page updated November 15, 2026 · transcript and summary are machine-generated